Protease Inhibitors in AIDS Therapy

Protease Inhibitors in AIDS Therapy

Marcel Dekker, 270 Madison Ave., New York, NY 10016. 310p., illus., bibliog., index. (Infectious Disease and Therapy, no. 25) ISBN 0-8247-0461-4. $125.00.
edited by Richard C. Ogden, Charles W. Flexner. 2001.

Antiretroviral therapy began with zidovudine (AZT), followed by aspartyl protease, and now protease inhibitors. There have been many advances in the research and use of protease inhibitors, the most dramatic being the decrease in the number of deaths from opportunistic infections. When first introduced, the protease inhibitors were intended to be the forerunner of a cure, but that has not happened. "This book provides a timely and comprehensive look at the class of HIV protease inhibitors from a scientific and clinical perspective."

The 13 chapters and postscript cover: "HIV-1 Protease as a Target for AIDS Therapy," "Discovery and Early Development of Saquinavir," "Discovery and Early Development of Ritonavir and ABT-378," "Discovery and Early Development of Indinavir," "Discovery and Development of Nelfinavir (Viracept)," "Design and Synthesis of Amprenavir, A Novel HIV Protease Inhibitor," "HIV Protease Inhibitors in Early Development," "Pharmacology and Drug Interactions of HIV Protease Inhibitors," "Beneficial Pharmacokinetic Interactions: Are Two Protease Inhibitors Better Than One," "Protease Inhibitors: Clinical Efficacy," "Toxicities and Adverse Effects of Protease Inhibitors," "Resistance to HIV-1 Protease Inhibitors," "Expedited Drug Approval and HIV Protease Inhibitors," and "Use of Protease Inhibitors in the Management of HIV/AIDS."

This is an excellent book that provides a history of protease inhibitors for the researcher. It is not a book for the layperson. "Many issues make HIV/AIDS a singular medical syndrome, in both the developed and developing worlds. The drugs described in this book--when used in combination with other antiretroviral agents--have extended and improved the lives of those living with the virus in many areas of the developed world. Their use has helped us understand the disease and to stimulate further AIDS research, the impact of which will be more global." This is a highly recommended book for all academic and health science libraries.

Keywords: Protease Inhibitors; Therapy)
010710
BK011080

Copyright © 2001 - The University of Illinois at Chicago. All materials in the journal are subject to copyright by the Board of Trustees of the University of Illinois and may be reprinted or redistributed for the noncommercial purpose of scientific or educational advancement granted by Sections 107 and 108 of the Copyright Revision Act of 1976. For other reprinting, redistribution, or translation, address requests to H. Robert Malinowsky, University of Illinois at Chicago Library, PO Box 8198, Chicago, IL 60680 or electronically to hrm@uic.edu.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .